B7H3-TF tag mRNA-LNP

B7H3 (B7 Homolog 3), also known as CD276, is encoded by the CD276 gene and is a member of the B7 family of immunomodulatory proteins. It is an immune checkpoint molecule and a co-stimulatory/co-inhibitory immunomodulatory protein that plays a dual role in the immune system. Transmembrane B7H3 is a type I transmembrane protein consisting of an extracellular domain, a transmembrane domain and a short intracellular domain. The extracellular domain of murine B7H3 consists of a pair of immunoglobulin variable and constant domains, whereas human B7H3 consists of two pairs due to exon duplication. Although B7H3 mRNA is expressed in most normal tissues, the expression of B7H3 protein in normal tissues is very limited due to the regulation by microRNAs. However, B7H3 protein is highly expressed in many different types of cancer. B7H3 is overexpressed in tumor tissues and participates in the shaping and development of the tumor microenvironment (TME). To date, many B7H3-based immunotherapeutic strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models.
This product is designed as a tool for the delivery and expression of human TF tagged B7H3 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of B7H3-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The B7H3-TF fusion protein is approximately 60 kD, consisting of B7H3 (534 amino acids) and a C-terminal TF tag (15 amino acids). The GenPept accession number for B7H3 is NP_001019907.